miércoles, 14 de abril de 2021

FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer | FDA

FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer | FDA

No hay comentarios:

Publicar un comentario